Can E6E7 Alter The Competitive Balance In The Crowded HPV Test Market?
By
Mark Ratner / Email the Author / IN VIVO November 2011, Vol. 29, No. 10
Around The Industry / Word Count: 1651 / Article # 2011800189
Executive Summary
The October introduction of Gen-Probe’s new cervical cancer screening test may up the stakes in the battle over market share in testing for HPV, the cause of cervical cancer. That’s good news for several companies. One is OncoHealth, which is developing a low-cost protein-based test for direct measurement of E6E7, two important oncoproteins associated with HPV progression to cancer that are a part of Gen-Probe’s new test panel.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.